In pathobiochemical research, interest has been most recently focused on antioxidants scavenging harmful free radicals, which are partly responsible for the development of various diseases in oxidative stress. The most efficient among exogen chain-breaking antioxidants is lipo-soluble vitamin E. The tocopheroxyl radical formed from vitamin E in the course of the protecting reactions is most efficiently reduced again into vitamin E by vitamin C. On the other hand, vitamin C, which has a synergic effect with vitamin E, can be regenerated in a redundant way by α-lipoic acid, ubiquinols and glutathione, furthermore glutaredoxin, thioredoxin and protein disulfide isomerase enzyme, as well as NADPH-dehydroascorbate reductase. In some pathogenic cases, vitamin E as a membrane stabilizer is capable of alleviating abnormal membrane fluidity, thus, the hemolysis of erythrocytes can be prevented by a small amount of this vitamin. Favourable results have been attained by applying vitamin E therapy in patients suffering from sickle cell anemia, erythropoietic protoporphyria, β-thalassemia, and the periventricular hemorrhage of premature infants. Vitamin E as a vitamin K antagonist decreases the synthesis of coagulatory factors. In addition vitamin E has a significant immunostimulatory effect. Vitamin E is applied as an adjuvant in the therapy of several diseases, such as cardiovascular diseases, atherosclerosis, diabetes, myopathy, polyneuropathy, tardive dyskinesia, chronic alcoholic liver disease, burn injuries, cataracta. The dose applied in the therapy is 200-800 mg/day and as a geriatric agent 200- 400 mg/day of vitamin E. Optimum dose for the human is 140 mg/day with combined administration of 250 mg/day vitamin C. In general up to 1600 mg/day, no side-effects have been observed and toxicity has not occurred even by applying a massive dose (2000-3000 mg/day).
|Number of pages||10|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Dec 1 1999|
ASJC Scopus subject areas